Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.36 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176928 | 0.79 | ADORA2A (0.44) | ADORA2AADORA1LMNASMN1; SMN2 | |
| SCHEMBL6209132 | 0.79 | ADORA2A (0.44) | ADORA2AADORA1LMNASMN1; SMN2 | |
| SCHEMBL6176939 | 0.74 | PDE10A (0.40) | PDE10APDE2APDE5APDE4APDE4D | |
| SCHEMBL7721294 | 0.74 | PDE10A (0.44) | PDE10APDE2APDE5APDE4APDE4D | |
| SCHEMBL6177911 | 0.73 | MEN1 (0.49) | ADORA2AADORA1LMNASMN1; SMN2IDO1 | |
| SCHEMBL29424702 | 0.72 | CSF1R (0.41) | PDE10ASMN1; SMN2 | |
| SCHEMBL22533558 | 0.72 | CSF1R (0.41) | PDE10ASMN1; SMN2 | |
| SCHEMBL734408 | 0.72 | PDE10A (0.48) | PDE10APDE2APDE5APDE4APDE4D | |
| SCHEMBL29663746 | 0.72 | PDE10A (0.48) | PDE10APDE2APDE5APDE4APDE4D | |
| SCHEMBL29480784 | 0.68 | APAF1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392280-A4 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | ADORA2A 4495/4885ADORA1 3559/4885PDE10A 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.